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Background: The outlook for patients with esophageal and gastric (EG) cancer
remains poor. Hence, there is a compelling need to identify novel treatment strategies
and complementary biomarkers. Programmed death ligand 1 (PD-L1) and mismatch
repair deficiency (dMMR) are putative biomarkers of response to immune-checkpoint
blockade, but their prognostic value and interrelationship in EG cancer have been
sparsely investigated.
Methods: Immunohistochemical expression of PD-L1 on tumour cells (TC) and
tumour-infiltrating immune cells (TIC), and of PD-1 (programmed death receptor 1) on
TIC was assessed using tissue microarrays with primary tumours and a subset of paired
lymph node metastases from a consecutive, retrospective cohort of 174 patients with
chemoradiotherapy-naïve EG adenocarcinoma. MMR proteins MLH1, PMS2, MSH2,
and MSH6 were assessed by immunohistochemistry. The total number (intratumoural,
tumour-adjacent, and stromal) of CD8+ T cells in each core was calculated by
automated analysis.
Results: High PD-L1 expression on both TC and TIC, but not PD-1 expression, was
significantly associated with dMMR. PD-L1 expression on TIC was significantly higher
in lymph node metastases than in primary tumours. High expression of PD-L1 or PD-1
on TIC was significantly associated with a prolonged survival, the former independently
of established prognostic factors. A significant stepwise positive association was found
between CD8+ T cells and categories of PD-L1 expression on TIC.
Conclusion: PD-L1 expression on TIC is higher in lymph node metastases compared
to primary tumours, correlates with dMMR, and is an independent factor of prolonged
survival in patients with chemoradiotherapy-naïve EG adenocarcinoma. These findings
suggest that PD-L1 expression on TIC may be a useful biomarker for identifying patients
who may not need additional chemo- or chemoradiotherapy, and who may benefit from
PD-1/PD-L1 immune-checkpoint blockade.
Keywords: PD-L1, PD-1, MMR status, MSI status, esophageal cancer, gastric cancer, the cancer genome atlas
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INTRODUCTION
Esophageal and gastric (EG) cancers constitute a
considerable proportion of cancer cases and deaths worldwide
(1). The outcome of these two cancer diagnoses is in general
poor, especially in Western populations with 5-year survival
rates being lower than 40%. Although addition of neoadjuvant
and adjuvant chemotherapy or chemoradiotherapy has led to
an improved survival in patients with resectable tumours (2–7),
there is still a great need to identify novel treatment strategies
and complementary biomarkers. Two biological therapies that
have shown efficacy for an improved overall survival (OS) in
the treatment of advanced EG cancer are trastuzumab and
ramucirumab, both monoclonal antibodies (mAb) targeting
the human epidermal growth factor receptor 2 (HER2) and
the vascular endothelial growth factor receptor 2 (VEGFR2),
respectively (8–10). Immune-checkpoint blockade, e.g., targeting
the programmed death receptor 1 (PD-1) pathway, is another
novel upcoming treatment option that has shown promising
results in various types of tumours, and the efficacy in EG cancer
is being investigated in several ongoing trials. For Asian patients
with heavily pretreated gastric or esophago-gastric junction
cancer, the ONO-4538-12, ATTRACTION-2 study (n = 493)
by Kang et al. has shown a significantly improved survival after
treatment with nivolumab, a human IgG4 monoclonal antibody
inhibitor of PD-1, compared to placebo (11). Expression of the
programmed death ligand 1 (PD-L1) is a putative biomarker
of response to such therapies (12), but the prognostic value
in EG cancer remains unclear. PD-L1 is expressed on both
tumour cells (TC) and tumour-infiltrating immune cells (TIC),
whereas PD-1 is only expressed on TIC. According to a report
encompassing 465 Caucasian gastric cancer cases, patients with
high expression of PD-L1 on both TC and TIC had the best OS.
In that study, PD-L1 was expressed on TC in 30% of the cases
and on TIC in 36% of the cases. Regarding PD-1, no expression
was observed on TC, whereas positive expression on TIC was
denoted in 54% of the cases, and PD-1 expression on TIC was
significantly associated with PD-L1 expression on both TC
and TIC (13). Some studies have however reported an adverse
association between PD-L1 expression and survival in gastric
cancer (14, 15). In an Asian study by Zhang et al. (n = 132)
PD-L1 expression was denoted in 51% of the gastric cancer
tumours, TC and/or TIC not specified, and the 5-year survival
rates was significantly better for PD-L1 positive patients. PD-1
status was not investigated in that study (15).
Abbreviations: EG, esophageal and gastric; OS, overall survival; mAb, monoclonal
antibodies; HER2, human epidermal growth factor receptor 2; VEGFR2, vascular
endothelial growth factor receptor 2; PD-1, programmed death receptor 1; PD-L1,
programmed death ligand 1; TC, tumour cells; TIC, tumour-infiltrating immune
cells; dMMR, mismatch repair deficiency; MSI, microsatellite instability; MSI-
H, MSI-High; ORR, objective response rate; MMR, mismatch repair; MAGIC,
Medical Research Council Adjuvant Gastric Infusional Chemotherapy; TCGA,
The Cancer Genome Atlas; TTR, time to recurrence; TMAs, tissue microarrays;
EBV, Epstein-Barr virus; EBER, EBV-encoded RNA; GDC, Genomic Data
Commons; FPKM, The fragments per kilobase of exon per million mapped
reads; HR, hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma;
TME, tumour microenvironment; TILs, tumour-infiltrating lymphocytes; IFNγ,
interferon-gamma.
Mismatch repair deficiency (dMMR), or microsatellite
instability (MSI), is another putative predictive biomarker of
response to immune-checkpoint blockade. In the KEYNOTE-
059 trial by Fuchs et al. (n = 259), investigating the response
rate of pembrolizumab, a humanized IgG4-κ monoclonal
antibody inhibitor of PD-1, in previously treated gastric and
esophago-gastric junction cancer, patients with MSI-High (MSI-
H) tumours had a higher objective response rate (ORR) than
non-MSI-H tumours, but, notably, the majority of responders
were non-MSI-H patients and only 4% of the tumours were MSI-
H (12). Regarding mismatch repair (MMR) status and prognosis
in gastric cancer, the reports are sparse and the results are
contrasting. For example, in a study by Marrelli et al. (n = 472),
an improved prognosis was demonstrated for patients with MSI-
H gastric tumours, even tumours with more advanced nodal
status, but the benefit was only confirmed in the non-cardia
subgroup, with intestinal-type or tubular/poorly differentiated
histology according to the WHO classification (16). On the
other hand, in a report by An et al. (n = 1990), there was
no difference in disease-free survival according to MSI status
(17). Furthermore, Smyth et al. showed, in a secondary post
hoc analysis of the Medical Research Council Adjuvant Gastric
Infusional Chemotherapy (MAGIC) trial, that patients with
dMMR tumours had a prolonged OS when treated with surgery
alone, compared to surgery and perioperative chemotherapy
together, proposing that perioperative chemotherapy may not be
beneficial for patients with dMMR tumours (18). In the MAGIC
trial, all dMMR tumours were found in the stomach, of note none
in the lower esophagus or esophago-gastric junction. To the best
of our knowledge, only one former study has investigated the
relationship between MMR status and prognosis in esophageal
adenocarcinoma and no significant association was found (19).
The aim of this study was to examine the expression of PD-L1
on TC and TIC, and PD-1 on TIC, in chemoradiotherapy-naïve
primary EG adenocarcinoma and paired lymph node metastases.
Particular attention was given to their relationship with MMR
status and prognosis. The prognostic value of PD-L1 and PD-1
expression at the mRNA level was also examined in 354 cases of
gastric cancer and 161 cases of esophageal cancer in The Cancer
Genome Atlas (TCGA). The association between CD8+ T cells
and the expression of PD-L1 on TC and TIC, and PD-1 on TIC,
in primary tumours was also investigated.
MATERIALS AND METHODS
Study Design and Participants
The study cohort encompasses a previously described
consecutive series of 174 patients with chemoradiotherapy-naïve
esophageal and gastric adenocarcinoma (20–22). All patients
were subjected to surgical resection at the University Hospitals
of Lund and Malmö between January 1, 2006 and December 31,
2010. Tumour location was determined on endoscopy findings
and classification of the tumour stage was done according to
the 7th edition of the UICC/AJCC TNM classification, in which
esophago-gastric junction tumours are classified as esophageal
tumours (23). However, in clinical practice, and according to
the new 8th edition of the UICC/AJCC TNM classification
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(24), esophago-gastric junction Siewert type 3 tumours are
managed as gastric cancer, hence this definition is used in our
subgroup analyses. Clinical data regarding recurrence and vital
status were obtained retrospectively from medical records and
the last update, with additional re-examination of some of the
clinicopathological data, reaches until March 2016. Time to
recurrence (TTR) was defined as time from diagnosis (date of
result of the preoperative biopsy) to the date of proven recurrent
disease (local, regional, or distant) by biopsy or radiology. TTR
was not calculated for patients with distant metastases (M1) or
macroscopic residual tumour (R2). OS was defined as time from
diagnosis (date of result of the preoperative biopsy) to the date of
death from any cause. Residual tumour status was classified as:
R0 = no residual tumour (free resection margins according to
pathology report), R1=microscopic residual tumour (narrow or
compromised resection margins according to pathology report),
R2 = macroscopic residual tumour (according to the operative
report). In the cohort, three patients had known M1-disease
at the time of surgery, and underwent surgery with the aim to
decrease symptoms from the primary tumour. The remainder
of the cohort, 98.7%, was operated on with a curative intent, but
in 16 of these patients, M1-disease was detected either during
surgery or postoperatively through pathological examination of
the resected specimen. Neoadjuvant or perioperative oncological
therapy was not given to any of the patients in this cohort.
Postoperative adjuvant treatment was given to 13 patients
(7.5%), of which 11 received chemoradiotherapy, 1 received
chemotherapy, and 1 received radiotherapy.
Tissue Microarray Construction
Tissue microarrays (TMAs) were constructed as previously
described using a semiautomated arraying device (TMArrayer,
Pathology Devices, Westminister, MD, USA) (20). Duplicate
tissue cores (1mm) were obtained from two different blocks from
all of the 174 primary tumours. Paired lymph node metastases
were sampled from 81 cases, also in duplicate cores and from
separate metastatic lymph nodes if more than one was present
and of sufficient size.
Immunohistochemical Staining
and Evaluation
For immunohistochemical analysis of MMR proteins, 4µm
TMA sections were automatically pretreated and stained using
the Benchmark Ultra Ventana platform. MMR status was
evaluated using “ready to use,” RTU, monoclonal antibodies
against MLH1 (Clone M1, Ventana/Roche, Basel, Schweiz,),
PMS2 (Clone EPR3947, Ventana/Roche, Basel, Schweiz), MSH2
(Clone G219-1129, Ventana/Roche, Basel, Schweiz) and MSH6
using a monoclonal antibody (EPR3945, Nordic Biosite, Taby,
Sweden) diluted 1:50. Immunohistochemical stainings were
denoted as negative when all TCs showed loss of nuclear staining.
Surrounding stromal cells and TICs served as internal controls
for each TMA core. Tumour samples lacking nuclear staining
of MLH1, PMS2, MSH2, or MSH6 were considered to have
dMMR status. For immunohistochemical analyses of PD-1 and
PD-L1, 4µm tissue sections were pre-treated using the DAKO
PT link system (DAKO; Glostrup, Copenhagen, Denmark) and
stained in an Autostainer Plus (Dako; Glostrup, Denmark) with
the anti PD-1 antibody NAT105, ab52587; Abcam, Cambridge,
MA, USA, diluted 1:50 and the anti PD-L1 E1L3N, Cell Signaling
Technology, Inc. (CST), Danvers, MA, USA) diluted 1:200. For
scoring of PD-L1 and PD-1 expression the percentage of stained
TIC was categorized as <10, 10–49, and 50–100%. For scoring
of PD-L1 expression on TC the percentage of stained cells was
categorized as<1, 1–4, 5–9, 10–49% and 50–100%, in accordance
with a previous study by Berntsson et al. (25). The annotation
of PD-L1 and PD-1 expression was carried out manually by two
independent observers (MS, KJ), the latter being a board certified
pathologist. Discrepant cases were re-evaluated and discussed in
order to reach consensus. Only lymph nodes with presence of
clearly visible metastatic tumour cells were evaluated for PD-L1
and PD-1 positive immune cells. The staining and automated
analysis of CD8+ T cells has been described previously (21).
EBER in situ Hybridization
For detection of Epstein-Barr virus (EBV)-infected tumours,
the presence of EBV-encoded RNA (EBER) transcripts was
analysed by chromogenic in situ hybridization on 4-µm-thick
TMA sections with appropriate controls, performed on the
Ventana Benchmark ULTRA automated platform (Ventana
Medical Systems, Tucson, AZ, USA) following themanufacturer’s
protocol. The EBER 1 DNP probe (760-1209, Ventana Medical
Systems) was used for detection, ISH iVIEW Blue Plus Detection
kit (760-097, Ventana Medical Systems) was used to produce the
chromogenic reaction, and slides were counterstained with Red
Counterstain II (780-2218, Ventana Medical Systems).
Survival Analysis Using TCGA Samples
Gastric and esophageal tumour samples were collected from
TCGA project from the Genomic Data Commons (GDC). The
fragments per kilobase of exon permillionmapped reads (FPKM)
values were retrieved and the average FPKM value was used
for all individual samples for each tissue to estimate PD-L1
and PD-1 gene expression levels. A cut-off value of 1 FPKM
was used as a detection limit across all tissues. The patients
were classified into two groups and their prognoses examined
based on the FPKM values. Genes with low expression were
excluded i.e., those with a median expression among samples
<1 during the analysis. The prognosis of each group of patients
was examined by Kaplan-Meier survival estimates. To choose
the best FPKM cut-offs for the most significant grouping of the
patients, FPKM values from the 20 to 80th percentiles were used
and significant differences in the survival outcomes of the groups
were examined.
Statistics
To evaluate associations between categories of PD-L1
expression on TC and TIC, and PD-1 expression on TIC,
and clinicopathological factors, Kruskal–Wallis test was used
for continuous variables and Chi-Square (linear-by-linear) test
for categorical variables. Wilcoxon signed-rank test was applied
to compare the distribution of PD-L1 and PD-1 expression in
primary tumours and paired lymph node metastases. Kaplan-
Meier analysis and the log rank test were applied to detect
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differences in TTR and OS. Cox proportional hazards models
were used to calculate univariable and multivariable hazard
ratios (HR) for TTR and OS. To assess the association between
CD8+ T cells with PD-L1 expression on TIC in primary tumours,
Mann-Whitney U-test was used.
The multivariable model included age, primary tumour
location, adjuvant treatment, T stage, N stage, M stage,
differentiation grade, residual tumour status, and MMR status.
The proportional hazards assumption was tested using Cox
regression with a time-dependent covariate analysis, whereby the
proportional hazard assumption was considered to be satisfied
when the factor x time interaction was non-significant.
All tests were two-tailed and p ≤ 0.05 were considered
significant. All calculations were performed using IBM SPSS
Statistics for Mac version 24.0 (IBM, Armonk, NY, USA).
RESULTS
Distribution of PD-L1 and PD-1 Expression
in Primary Tumours and Paired Lymph
Node Metastases
In primary tumours, PD-L1 expression on TC and TIC could
be evaluated in 165/174 (94.8%) cases. Positive (≥ 1%) PD-L1
TC expression was denoted in 38 (23.0%) cases and positive
(>10%) PD-L1 TIC expression in 68 (41.2%) cases. In paired
lymph node metastases, PD-L1 expression on TC and TIC
could be evaluated in 68/81 (84.0%) cases. Positive PD-L1 TC
expression was denoted in 12 (17.6%) cases and positive PD-
L1 TIC expression in 37 (54.4%) cases. In primary tumours,
PD-1 expression on TIC could be evaluated in 170/174 (97.7%)
cases. Positive (>10%) PD-1 TIC expression was denoted in 86
(50.6%) cases. In paired lymph node metastases, PD-1 expression
on TIC could be evaluated in 75 (92.6%) cases. Positive PD-
1 TIC expression was denoted in 40 (53.3%) cases. Sample
immunohistochemical images are shown in Figure 1.
Correlation Between PD-L1 and PD-1
Expression in Primary Tumours and Paired
Lymph Node Metastases
Bar charts visualising the distribution of PD-L1 and PD-
1 expression in primary tumours and paired lymph node
metastases, respectively, are shown in Figure 2. PD-L1
expression on TIC was significantly higher in lymph node
metastases compared to primary tumours (p = 0.009). There
was no significant difference in PD-L1 expression on TC or
PD-1 expression on TIC between primary tumours and lymph
node metastases.
Associations With Clinicopathological
Factors and Intercorrelation of PD-L1 and
PD-1 Expression
The associations of PD-L1 and PD-1 expression with tumour
and patient characteristics, as well as the intercorrelations of PD-
L1 and PD-1 expression are shown in Table 1. Increased PD-
L1 expression on TC was significantly associated with higher
grade (p = 0.013) and dMMR (p < 0.001). Increased PD-
L1 expression on TIC was significantly associated with lower
T stage (p = 0.018), lower N stage (p = 0.001), lower M
stage (p = 0.044) and dMMR (p < 0.001). Increased PD-1
expression on TIC was significantly associated with lower T
stage (p = 0.049) and lower N stage (p = 0.027). Furthermore,
there were moderate significant intercorrelations between PD-
L1 and PD-1 expression on TC and TIC, and PD-1 expression
on TIC, respectively (p < 0.001 for all, R = 0.312–0.412).
The associations of PD-L1 and PD-1 expression with tumour
and patient characteristics, as well as the intercorrelations of
PD-L1 and PD-1 expression in esophageal and gastric cancer,
respectively, are shown in Supplementary Tables S1, S2. Three
(4.1%) out of 74 evaluable gastric cancers were positive for EBER
mRNA, and all 95 evaluable esophageal cancers were negative.
As shown in Supplementary Table S2, PD-L1 expression on TC
was significantly higher in EBV-associated tumours, whereas PD-
L1 or PD-1 expression on TIC did not differ by EBV status.
Of note, all EBV-associated tumours had ≥ 10% PD-L1 positive
TC (data not shown). As a common feature, all three EBV-
associated tumours were located in the corpus, had pMMR
status, were high-grade, radically resected and none had distant
metastases. Two cases were of diffuse type and one of intestinal
type according to the Laurén classification, two had N0 and one
had N1 status, and the distribution of T stages was 2, 3, and 4. All
three patients with EBV-associated tumours, one woman and two
men, none of whom received adjuvant chemotherapy, were alive
at last follow-up (data not shown).
Prognostic Significance of PD-L1
Expression on TC and TIC and PD-1
Expression on TIC in Primary Tumours
Kaplan-Meier analyses of the prognostic impact of PD-L1
expression on TC and TIC and PD-1 expression on TIC are
shown in Figure 3. High PD-L1 and PD-1 expression on TIC
was significantly associated with a prolonged OS (p = 0.023
and p = 0.004, respectively). PD-L1 expression on TC was not
prognostic. Similar results were found for TTR and are shown in
Figure 4. For Cox regression analyses, PD-L1 expression on TIC
was dichotomised at 0–49 vs. ≥ 50% and PD-1 expression was
dichotomised at 0–9 vs. ≥ 10%. The time-dependent covariate
was non-significant for both PD-L1 and PD-1 expression, and
therefore, the factor x time interaction term was dropped
from the model. The proportional hazard assumption was also
considered to be satisfied with graphical evaluation using log-
minus-log plots (data not shown). As shown in Table 2, the
prognostic value regarding OS was confirmed for both PD-
L1 and PD-1 on TIC in univariable analysis (HR = 0.35,
95% confidence interval [CI] = 0.14–0.87, and HR = 0.60,
95% CI = 0.42–0.85, respectively), and remained significant
for PD-L1 but not PD-1 in multivariable analysis (HR = 0.39,
95% CI = 0.15–0.99). As shown in Table 3, both PD-L1 and
PD-1 expression on TIC remained prognostic also regarding
TTR in univariable analysis (HR = 0.20, CI = 0.05–0.80,
and HR = 0.44, CI = 0.28–0.70, respectively), but not in
multivariable analyses.
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FIGURE 1 | Immunohistochemical expression of PD-1 and PD-L1 in the primary tumour (left) and a paired lymph node metastasis (right) from an esophageal (cardia
Siewert 1) pT3N3M0 tumour. PD-1 and PD-L1 positivity was denoted in >50% of the immune cells, and PD-L1 positivity was denoted in >50% of the tumour cells.
Arrowheads with solid lines denote PD-L1 positive tumour cells and arrowheads with dashed lines denote PD-L1 positive immune cells. In general, PD-L1 positive
immune cells in the lymph nodes were located in the vincinity of the metastatic deposits.
FIGURE 2 | Bar charts visualising the distribution of PD-L1 expression on (A) tumour cells and (B) tumour-infiltrating immune cells and (C) the distribution of PD-1
expression on tumour-infiltrating immune cells, in primary tumours and paired lymph node metastases, in the entire cohort; (A) p = 1.000, (B) p = 0.009, (C)
p = 0.180.
Prognostic Impact of PD-L1 and PD-1
mRNA Expression
Kaplan-Meier analyses of OS according to PD-L1 and PD-1
mRNA expression in 354 cases of gastric cancer and 161
cases of esophageal cancer in TCGA are shown in Figure 5.
PD-L1 expression was not prognostic at the transcript
level in neither esophageal nor gastric cancer. High PD-1
expression was significantly associated with a prolonged
OS in gastric cancer (p = 0.041), whereas a borderline
significant association was observed between high PD-1
expression and a shorter OS (p = 0.053) in esophageal
cancer. Of note, both squamous cell carcinoma (SCC)
and adenocarcinoma are included in the esophageal cancer
dataset in TCGA.
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TABLE 1 | Associations with clinicopathological factors and intercorrelation of PD-L1 and PD-1 expression.
Factor PD-L1 Tumour cells PD-L1 Immune cells PD-1 Immune cells
n(%) <1% 1–49% ≥50% P 0–10% 11–50% >50% P 0–10% 11–50% >50% P
127 (73.0) 33 (19.0) 5 (2.9) 97 (55.7) 56 (32.2) 12 (6.9) 84 (49.4) 80 (47.1) 6 (3.5)
AGE
Mean, median 69.2, 67.8 72.2, 72.9 76.4, 77.6 0.140 68.2, 67.7 71.7,71.5 76.4,80.6 0.028 70.5,71.4 70.0,69.3 75.6,77.8 0.425
(range) (42.6–94.4) (48.7–88.6) (62.7–86.1) (42.6–88.8) (50.2–94.4) (58.6–86.1) (42.6–88.8) (48.3–94.4) (62.7,-83.1)
GENDER
Female 26 (20.5) 9 (27.3) 3 (60.0) 0.062 23 (23.7) 12 (21.4) 3 (25.0) 0.901 14 (16.7) 24 (30.0) 1 (16.7) 0.115
Male 101 (79.5) 24 (72.7) 2 (40.0) 74 (76.3) 44 (78.6) 9 (75.0) 70 (83.3) 56 (70.0) 5 (83.3)
T STAGE
T1 12 (9.4) 3 (9.1) 0 (0.0) 0.432 8 (8.2) 6 (10.7) 1 (8.3) 0.018 6 (7.1) 10 (12.5) 0 (0.0) 0.049
T2 21 (16.5) 8 (24.2) 1 (20.0) 13 (13.4) 12 (21.4) 5 (41.7) 10 (11.9) 20 (25.0) 2 (33.3)
T3 71 (55.9) 19 (57.6) 4 (80.0) 56 (57.7) 32 (57.1) 6 (50.0) 53 (63.1) 38 (47.5) 4 (66.7)
T4 23 (18.1) 3 (9.1) 0 (0.0) 20 (20.6) 6 (10.7) 0 (0.0) 15 (17.9) 12 (15.0) 0 (0.0)
N STAGE
N0 37 (29.1) 15 (45.5) 1 (20.0) 0.152 24 (24.7) 21 (37.5) 8 (66.7) 0.001 17 (20.2) 37 (46.3) 2 (33.3) 0.027
N1 20 (15.7) 7 (21.2) 2 (40.0) 14 (14.4) 14 (25.0) 1 (8.3) 19 (22.6) 9 (11.3) 1 (16.7)
N2 36 (28.3) 3 (9.1) 1 (20.0) 28 (28.9) 10 (17.9) 2 (16.7) 22 (26.2) 19 (23.8) 0 (0.0)
N3 34 (26.8) 8 (24.2) 1 (20.0) 31 (32.0) 11 (19.6) 1 (8.3) 26 (31.0) 15 (18.8) 3 (50.0)
M STAGE
M0 110 (86.6) 31 (93.9) 5 (100.0) 0.154 82 (84.5) 52 (92.9) 12 (100.0) 0.044 75 (89.3) 72 (90.0) 4 (66.7) 0.460
M1 17 (13.4) 2 (6.1) 0 (0.0) 15 (15.5) 4 (7.1) 0 (0.0) 9 (10.7) 8 (10.0) 2 (33.3)
GRADE
Low 49 (38.6) 7 (21.2) 0 (0.0) 0.013 29 (29.9) 22 (39.3) 5 (41.7) 0.206 26 (31.0) 32 (40.0) 0 (0.0) 0.861
High 78 (61.4) 26 (78.8) 5 (100.0) 68 (70.1) 34 (60.7) 7 (58.3) 58 (69.0) 48 (60.0) 6 (100.0)
RESIDUAL TUMOUR STATUS
R0 84 (66.1) 22 (66.7) 4 (80.0) 0.660 60 (61.9) 39 (69.6) 11 (91.7) 0.058 55 (65.5) 56 (70.0) 4 (66.7) 0.883
R1 36 (28.3) 9 (27.3) 1 (20.0) 31 (32.0) 14 (25.0) 1 (8.3) 26 (31.0) 18 (22.5) 2 (33.3)
R2 7 (5.5) 2 (6.1) (0.0) 6 (6.2) 3 (5.4) 0 (0.0) 3 (3.6) 6 (7.5) 0 (0.0)
LOCATION
Esophagus 75 (59.1) 18 (54.5) 2 (40.0) 0.390 50 (51.5) 37 (66.1) 8 (66.7) 0.083 52 (61.9) 41 (51.3) 3 (50.0) 0.176
Stomach 52 (40.9) 15 (45.5) 3 (60.0) 47 (48.5) 19 (33.9) 4 (33.3) 32 (38.1) 39 (48.8) 3 (50.0)
LAURÉN
Intestinal 87 (68.5) 22 (66.7) 4 (80.0) 0.894 63 (64.9) 40 (71.4) 10 (83.3) 0.255 58 (69.0) 54 (67.5) 4 (66.7) 0.709
Mixed 7 (5.5) 2 (6.1) 0 (0.0) 7 (7.2) 2 (3.6) 0 (0.0) 5 (6.0) 4 (5.0) 0 (0.0)
Diffuse 33 (26.0) 9 (27.3) 1 (20.0) 27 (27.8) 14 (25.0) 2 (16.7) 21 (25.0) 22 (27.5) 2 (33.3)
MMR STATUS
pMMR 124 (97.6) 25 (75.8) 3 (60.0) <0.001 95 (97.9) 49 (87.5) 8 (66.7) <0.001 78 (92.9) 74 (92.5) 4 (66.7) 0.233
dMMR 3 (2.4) 8 (24.2) 2 (40.0) 2 (2.1) 7 (12.5) 4 (33.3) 6 (7.1) 6 (7.5) 2 (33.3)
PD-L1 TUMOUR CELLS
<1% – – – 89 (91.8) 31 (55.4) 7 (58.3) <0.001 71 (88.8) 53 (68.8) 1 (16.7) <0.001
1–49% – – – 7 (7.2) 24 (42.9) 2 (16.7) 7 (8.8) 22 (28.6) 4 (66.7)
≥50% – – – 1 (1.0) 1 (1.8) 3 (25.0) 2 (2.5) 2 (2.6) 1 (16.7)
PD-L1 IMMUNE CELLS
0–10% 89 (70.1) 7 (21.2) 1 (20.0) <0.001 – – – 61 (76.3) 33 (42.9) 1 (16.7) <0.001
11–50% 31 (24.4) 24 (72.7) 1 (20.0) – – – 17 (21.3) 35 (45.5) 4 (66.7)
>50% 7 (5.5) 2 (6.1) 3 (60.0) – – – 2 (2.5) 9 (11.7) 1 (16.7)
PD-1 IMMUNE CELLS 61 (64.2) 17 (30.4) 2 (16.7) <0.001
0–10% 71 (56.8) 7 (21.2) 2 (40.0) <0.001 33 (34.7) 35 (62.5) 9 (75.0) – – –
11–50% 53 (42.4) 22 (66.7) 2 (40.0) 1 (1.1) 4 (7.1) 1 (8.3) – – –
>50% 1 (0.8) 4 (12.1) 1 (20.0) – – –
MMR, mismatch repair; pMMR, mismatch repair proficiency; dMMR, mismatch repair deficiency.
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FIGURE 3 | Kaplan-Meier analysis of OS in strata according to immunohistochemical staining categories of (A) PD-L1 expression on, (B) PD-L1 expression on, and
(C) PD-1 expression on in the entire cohort. (A)<1% = ref, 1–4% p = 0.285, 5–9% p = 0.815, 10–49% p = 0.721, 50–100% p = 0.763, (B)<10% = ref, 10–49%
p = 0.512, 50–100% p = 0.014, (C)<10% = ref, 10–49% p = 0.003, 50–100% p = 0.842.
FIGURE 4 | Kaplan-Meier estimates of TTR in strata according to immunohistochemical staining categories of (A) PD-L1 expression on, (B) PD-L1 expression on and
(C) PD-1 expression on in the entire cohort. (A) <1% = ref, 1–4% p = 0.803, 5–9% p = 0.244, 10–49% p = 0.815, 50–100% p = 0.603, (B) <10% = ref, 10–49%
p = 0.484, 50–100% p = 0.010, (C) <10% = ref, 10–49% p = 0.000, 50–100% p = 0.824.
Associations of MMR Status With
Clinicopathological Factors and Prognosis
In the entire cohort, 14 (8.1%) primary tumours had dMMR
status. The distribution of these cases according to anatomical
subsite was; 3 (7.5%) in the lower third of the esophagus including
esophago-gastric junction (Siewert type 1), 3 (13.0%) in the true
cardia (Siewert type 2), 1 (11.1%) in the subcardial stomach
(Siewert type 3), 1 (50.0%) in fundus, 3 (8.3%) in corpus, 2 (8.7%)
in antrum and 1 (20.0%) in pylorus.
Associations of MMR status with tumour and patient
characteristics are shown in Supplementary Table S3. dMMR
was significantly associated with higher age (p= 0.001) and lower
N stage (p = 0.012). Kaplan-Meier analyses of the prognostic
impact of MMR status are shown in Figure 6. Similar and non-
significant results were found for TTR (data not shown).
Associations of CD8+ T Cells With PD-L1
Expression on TC and TIC and PD-1
Expression on TIC in Primary Tumours
The associations of CD8+ T cells with PD-L1 expression on TIC
in primary tumours in the entire cohort are shown in Figure 7.
There was a significant stepwise positive association between
CD8+ T cell density and categories of in particular PD-L1, but
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TABLE 2 | Cox proportional hazards analysis of the impact of PD-L1 and PD-1
immune cell density on overall survival in the entire cohort.
OS
n (events) HR (95 % CI) P
PD-L1
Univariable
Low 153 (116) 1.00
High 12 (5) 0.35 (0.14–0.87) 0.023
Multivariable
Low 153 (116) 1.00
High 12 (5) 0.39 (0.15–0.99) 0.048
PD-1
Univariable
Low 84 (70) 1.00
High 86(56) 0.60 (0.42–0.85) 0.004
Multivariable
Low 84 (70) 1.00
High 86 (56) 0.70 (0.46–1.05) 0.086
OS, overall survival; HR, hazard ratio; CI, confidence interval. Multivariable analysis
includes age, location, adjuvant treatment, T stage, N stage, M stage, differentiation grade
(high vs. low), resection margins (R0,R1,R2), mismatch repair status.
also PD-1, expression, on TIC. The associations between CD8+
T cells and PD-L1 on TC were less evident.
DISCUSSION
This is one of few studies that has investigated the
intercorrelation between PD-L1 and PD-1 expression in
primary tumours and paired lymph node metastases, as well
as the relationship between MMR status and prognosis, in
esophageal adenocarcinoma.
High expression of both PD-L1 and PD-1 on TIC was
significantly associated with a prolonged OS, the former
independently of other prognostic factors and MMR status.
These findings are partly in line with the study by Böger et al.
on gastric cancer wherein patients with high expression of PD-
L1 on TIC had a significantly better OS in both univariable and
multivariable analysis and patients with high expression of PD-
L1 on TC had a significantly improved survival in univariable
analyses. However, patients with high PD-L1 expression on both
TC and TIC had the best OS (13). Of note, the present study
and the study by Böger et al. utilized the same monoclonal
antibody for PD-L1 staining. In contrast, other studies have
demonstrated associations between positive PD-L1 expression
and poor survival, e.g., Zhang et al. (15). Of note, all tumours in
the present study as well as in the study by Böger et al. (13) and
Zhang et al. (15) were derived from patients who did not receive
neoadjuvant therapy, which makes the cohorts comparable.
Regarding PD-1 expression and its association with prognosis,
only a few studies have investigated this in EG cancer, and no
significant associations have been found besides from one Asian
study on gastric cancer by Gao et al. (n = 119) wherein PD-1
expression on CD8+ T cells was found to be an unfavourable
TABLE 3 | Cox proportional hazards analysis of the impact of PD-L1 and PD-1
immune cell density on time to recurrence in the entire cohort.
TTR
n (events) HR (95 % CI) P
PD-L1
Univariable
Low 128 (77) 1.00
High 11 (2) 0.20 (0.05–0.80) 0.023
Multivariable
Low 128 (77) 1.00
High 11 (2) 0.75 (0.22–2.58) 0.647
PD-1
Univariable
Low 73 (50) 1.00
High 71 (30) 0.44 (0.28–0.70) 0.001
Multivariable
Low 73 (50) 1.00
High 71 (30) 0.87 (0.52–1.46) 0.602
TTR, time to recurrence; HR, hazard ratio; CI, confidence interval. Multivariable analysis
includes age, location, adjuvant treatment, T stage, N stage, M stage, differentiation grade
(high vs. low), resection margins (R0,R1,R2), mismatch repair status.
prognostic factor, but no other types of immune cells were
explored regarding PD-1 expression (26). In the study by
Böger et al. patients with PD-1 positive gastric tumours had
a better tumour specific survival, however only borderline
significant (13). In another study on chemoradiotherapy-naïve
esophageal cancer (n = 354), PD-1 positivity correlated with
increased mortality, but not after adjusting for other prognostic
factors (27).
The expression of PD-L1 and PD-1 on TC and TIC in this
study is well in line with the above mentioned study by Böger
et al. (13). Furthermore, PD-L1 expression on TIC was found
to be significantly higher in lymph node metastases compared
to primary tumours, whereas the expression of PD-L1 on TC
and PD-1 on TIC did not differ between primary tumours and
lymph node metastases. The previously mentioned study on
gastric cancer, by Böger et al. showed a concordance between
the expression of PD-L1 on TC and TIC and PD-1 on TIC
in liver metastases (n = 15) and primary tumours (13). In the
study on gastric cancer by Gao et al. the positive rate of PD-L1
expression on TC was found to be higher in metastatic lymph
nodes (n = 119) than in primary tumours, TIC not investigated
(26). Of note, the present study and the study byGao et al. utilized
the same monoclonal antibody for PD-L1 staining. Furthermore,
Dislich et al. analysed PD-L1 expression on TC and TIC in
primary esophageal adenocarcinoma (n = 112), paired lymph
node metastases (n = 55) and distant metastases (n = 17), and
concluded that the expression in the different entities “does not
necessarily correlate” (19). The expression of PD-L1 in primary
tumours and lymph node metastases has also been investigated
in some other types of cancer, with divergent results. In a
study by Li et al. (n = 101) PD-L1 expression was compared
between primary triple negative breast tumours and axillary
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FIGURE 5 | Kaplan-Meier estimates of OS in strata according to high and low (A) PD-L1 and (B) PD-1 mRNA expression in gastric cancer and high and low (C)
PD-L1 and (D) PD-1 mRNA expression, in esophageal cancer, in TCGA. (A) p = 0.116, (B) p = 0.041, (C) p = 0.168, (D) p = 0.053.
lymph nodes (n= 101), whereby PD-L1 expression was found to
be significantly higher in both lymphocytes and TC of the axillary
lymph node metastases compared to the primary tumours (28).
On the other hand, in a study by Heeren et al. comparing PD-
L1 expression in primary tumours (n = 205) and paired lymph
nodemetastases (n= 127) in cervix squamous cell carcinoma and
adenocarcinoma no significant difference was found (29).
The findings from our study, as well as from the study
by Böger et al. (13) and Gao et al. (26) may be of potential
clinical relevance as they suggest that analysis of a biopsy
from a metastasis may also provide prognostic or predictive
information. Furthermore, the results in our study reflects the
heterogeneity of PD-L1 expression between primary tumours
and lymph node metastases, which is in line with other
previous studies (26, 30, 31). The findings may also contribute
predictive information in cases where treatment with immune-
checkpoint blockade targeting the PD-1/PD-L1 pathway is
considered, provided PD-L1 expression can be implemented
as a predictive biomarker for such therapy. However, before
this can be implemented in clinical protocols, further studies
are needed to investigate how neoadjuvant chemotherapy or
chemoradiotherapy may affect the quantity of PD-L1 and PD-1
positive cells in the tumour microenvironment (TME).
To validate our data, the prognostic value of PD-L1 and PD-
1 expression was also examined at the mRNA level in 354 cases
of gastric cancer and 161 cases of esophageal cancer in TCGA.
PD-L1 mRNA levels were not found to confer any prognostic
information. This is however not surprising, as our data clearly
demonstrate a prognostic value only for PD-L1 expression on
TIC and not on TC, and mRNA levels of PD-L1 represent a
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FIGURE 6 | Kaplan-Meier estimates of OS in strata according to MMR status in (A) the entire cohort, p = 0.626, (B) esophageal tumours, p = 0.824, and (C) gastric
tumours, p = 0.740.
FIGURE 7 | Box plots visualising the associations of CD8+ T cells with (A) PD-L1 expression on tumour cells and (B) PD-L1 expression on tumour-infiltrating immune
cells and (C) PD-1 expression on tumour-infiltrating immune cells, in primary tumours in the entire cohort.
mixture of TIC and TC. Regarding PD-1, high mRNA expression
was found to be significantly associated with a prolonged OS in
gastric cancer, thus validating the immunohistochemical data,
whereas a borderline significant trend towards an association
with a shorter OS was seen in esophageal cancer. A possible
explanation for the contrasting findings in gastric and esophageal
cancer could be that TCGA esophageal cancer dataset includes
both SCC and adenocarcinoma, which may cloud the results, as
esophageal SCC and adenocarcinoma have distinct and divergent
molecular characteristics (32).
In this study, no significant associations were found between
MMR status and clinical outcome. This is in line with
some previous studies, for example the study on esophageal
adenocarcinoma by Dislich et al. (19) and a meta-analysis on
gastric cancer by Polom et al. (33), but as mentioned before,
the number of studies on this topic is sparse and the results are
contrasting (16, 17, 33, 34).
The present study demonstrates a significant association
between dMMR tumours and an increased PD-L1 expression
on TC and/or TIC which is consistent with a study on gastric
cancer by Kawazoe et al. (n = 487), wherein PD-L1 positivity
(≥ 1%) on both TC and TIC was more frequently observed
in dMMR tumours (35). The patients included in the Kawazoe
study did not receive any chemotherapy before surgery which
makes the cohorts comparable. In the study by Böger et al. PD-
L1 expression on TC but not on TIC was found to correlate with
dMMR (13).
Furthermore, it could be hypothesized that the beneficial
prognostic outcome for patients with tumours displaying high
expression of PD-L1 on TIC, is due to the significant positive
association of CD8+ T cell density and PD-L1 expression on
TIC. Regarding gastric cancer, an Asian study by Wang et al.
(n= 509) demonstrated that patients with positive (>5%) PD-L1
TC expression and high CD8+ T cell infiltration was associated
with an improved OS, and positive PD-L1 status correlated with
high CD8+ T cell infiltration. PD-L1 expression on TIC was
not investigated (36). Similar results were found in the study by
Kawazae et al. wherein positive PD-L1 expression on both TC
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and TIC was investigated and found to be significantly associated
with high CD8+ T cell density. High density of CD8+ T cells was
also found to be an independent beneficial prognostic factor for
better survival (35). On the other hand, in the above mentioned
study by Gao et al. PD-L1 expression on TC and a high density
of CD8+ T cells were prognostic factors for shorter disease-free
survival, furthermore PD-L1 expression on TC was found to be
associated with CD8+ T cell density in the primary tumour (26).
It must however be kept in mind that the TME is highly complex,
with several undiscovered interactions. Furthermore, IHC only
mirrors a temporary reflection of its dynamic landscape. The
classification of tumours into different TME subgroups has been
suggested on the basis of PD-L1 expression, and the presence
or absence, of tumour-infiltrating lymphocytes (TILs), including
CD8+ T cells (37). This classification was initially proposed
in melanoma by Teng et al. (37) but has recently also been
applied in gastric tumours in a study by Cho et al. (n = 247)
wherein the PD-L1 TC positive/TIL positive TME subgroup,
was found to be more frequent in EBV-positive and MSI-H
gastric tumours and also to be associated with a favourable
prognosis (38). Of note, 50% of EBV-positive and 60% of MSI-
H tumours demonstrated high levels of PD-L1 expression (38).
Several studies, including the study by Teng et al. and Cho
et al. have discussed the putative mechanism by which the TCs
enhance their PD-L1 expression due to external stimuli from
TILs e.g., CD8 + T cells. (38–42). Taken together it has been
proposed that interferon-gamma (IFNγ), which is secreted by
activated CD8+ T cells, upregulates the PD-L1 TC expression
and hence, TCs escape immune surveillance by paralyzing and
disabling the CD8+ T cells to attack (40, 41). However, CD8+
T cells themselves are also promoted by IFNγ (42) which could
mean that if we reach a positive balance in the TME wherein
the beneficial effects of IFNγ bridges the unfavourable effects
of PD-L1, the net contribution may be an improved tumour
surveillance. Accordingly, this could potentially strengthen the
hypothesis that the beneficial prognostic value of high PD-L1
TIC expression in EG adenocarcinoma is due to its positive
association with CD8+ T cell density, as demonstrated in the
present study. In the study by Mimura et al. it is proposed
that gastric tumours with CD8+ T cells in the TME would be
more susceptible to PD-1/PD-L1 blockade (40). Possibly, the
higher expression of PD-L1 in lymph nodes as compared to
primary tumors may also have a relation to the presence of
IFNγ producing CD8+ T cells and other immune cells being
accumulated in lymph nodes.
A possible limitation to this study is the known heterogeneity
of PD-L1 expression. For example, in a study on non-small
cell lung cancer (n = 160), lung biopsies and corresponding
tumours were compared regarding PD-L1 expression, and the
expression was found to be lower in the biopsy compared to
the resected tumour in all cases, in particular the expression
on TIC (43). For gastric cancer, the heterogeneity of PD-
L1 was investigated in a study by Wang et al. (n = 550)
also demonstrating lower expression in TMA cores compared
to the whole tissue blocks, although the use of two cores,
one central and one from the invasive front, was thought to
minimize the heterogeneity issue (44). In our study, duplicate
tissue cores were also obtained from two different blocks from
all of the 174 primary tumours, and from the paired lymph
node metastases duplicate cores were sampled from separate
metastatic lymph nodes if more than one was present and of
sufficient size. Moreover, in a recent study on colorectal cancer,
a good concordance was demonstrated between PD-L1 and PD-
1 expression in TMA cores compared to whole tissue sections
(25). Another limitation that could be argued is the use of
different PD-L1 antibodies in different studies. We utilized the
platform independent clone E1L3N, which according to a recent
study on primary and metastatic bladder cancer (n = 156)
is comparable to the 3 FDA-approved clones 22C3, 28.8 and
SP142 (45).
The frequency of EBV-associated gastric tumours in the herein
analysed cohort (4.1%) is well in line with a study by Böger
et al. (n = 484), wherein 5.0% of all gastric adenocarcinomas
were found to be EBV-associated (46). According to a meta-
analysis by Murphy et al. around 8% of all gastric tumours
are EBV-positive (47). These tumours mostly occur in the
proximal part of the stomach (47–49) and are associated
with an elevated PD-L1 TC and /or TIC expression (13,
48). In the present study, only PD-L1 expression on TC was
significantly higher in the small number of EBV-associated
tumours. Moreover, as also shown in this study, patients with
EBV-associated tumours have an improved survival (50) and,
in addition, they appear to benefit from PD-1/PD-L1 blockade
(46, 48).
In conclusion, the results from this study demonstrate
that PD-L1 expression on TIC is higher in lymph node
metastases compared to primary tumours, correlates with
dMMR, and is an independent factor of prolonged survival
in patients with chemoradiotherapy-naïve EG adenocarcinoma.
The prognostic value of PD-1 expression was only evident
in unadjusted analysis and PD-L1 expression on TC did
not confer any prognostic value. Given the cell-type specific
prognostic impact of PD-L1 expression, assessment of PD-
L1 mRNA expression is not likely to be a useful tool in
the clinical setting. Taken together, these findings suggest
that PD-L1 expression on TIC may be a useful biomarker
for identifying patients who may not benefit from additional
chemo-or chemoradiotherapy before curative surgery, and in
the future, the prognostic information can also be of great
interest when considering treatment with immune-checkpoint
blockade targeting the PD-1/PD-L1 pathway, provided that PD-
L1 expression can be implemented as a predictive biomarker for
such therapy.
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